Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Molecular Medicine
• Drug Delivery Systems

Background:

• The COVID-19 pandemic highlighted the potential of nucleic acid therapeutics, including messenger RNA (mRNA) vaccines.
• Nucleic acid drugs offer a new era in medicine, targeting diseases at the genetic level for potentially curative effects.
• Significant challenges remain, including poor physicochemical properties, nuclease degradation, off-target toxicity, and immunogenicity, hindering clinical translation.

Purpose of the Study:

• To outline research on developing technology platforms to overcome pharmaceutical bottlenecks for nucleic acid therapeutics.
• To present engineered delivery systems and sequence modification strategies to improve nucleic acid drug performance.
• To offer insights into the rational design of advanced nucleic acid therapeutic platforms for enhanced efficacy and safety.

Main Methods:

• Development of intelligent delivery platforms: synthetic nanomaterials (lipid nanoparticles, polymers, inorganic nanoparticles), physical methods (electroporation), and natural vehicles (extracellular vesicles).
• Engineering delivery systems for improved circulation stability, targeting affinity, cellular internalization ('Get in'), and endolysosomal escape ('Get out').
• Implementing sequence engineering strategies to enhance nuclease resistance, translation efficiency, potency, and reduce off-target toxicity and immunogenicity.

Main Results:

• Demonstrated engineered delivery platforms capable of improving key pharmacokinetic and pharmacodynamic properties of nucleic acid therapeutics.
• Developed sequence modification strategies that enhance drug potency and safety profiles.
• Integrated approaches show promise for developing nucleic acid therapeutics with potent efficacy and improved safety.

Conclusions:

• Overcoming pharmaceutical bottlenecks through innovative delivery platforms and sequence engineering is crucial for advancing nucleic acid therapeutics.
• The developed technologies offer a pathway to enhanced stability, targeting, cellular entry, and endolysosomal escape.
• Continued advances and academic-industry collaborations are expected to accelerate the clinical translation of nucleic acid-based medicines.